How Fungi Can Make Asthma Worse and What to Do About It

Hello, dear members and subscribers of the World Asthma Foundation! We hope you are doing well and breathing easy. In this post, we are going to share with you some news about our Defeating Asthma initiative and our continuing series on Severe Asthma.

As you may know, the World Asthma Foundation is a community-based non profit that aims to raise awareness, provide education and support, and advocate for better care and treatment for people living with Asthma. We believe that everyone deserves to breathe freely and enjoy life without the burden of Asthma.

One of our main goals is to shed light on the different types of asthma and how they affect people differently. As most of you already know, Asthma is not a one-size-fits-all condition. It has many subtypes or phenotypes and some yet to be discovered that have different causes, triggers, symptoms, and responses to treatment. Understanding your Asthma phenotype can help you and your doctor find the best management plan for you.

That’s why we continue our focus on Severe Asthma, a challenging form of Asthma that affects about 5-10% of people with Asthma and consumes 80 % of the dollars to treat. Severe Asthma is often difficult to control with standard medications and can have a significant impact on your quality of life, health, and well-being.

One of the possible factors that can contribute to severe asthma is fungi. Fungi are microscopic organisms that are found everywhere in the environment. They can grow on plants, animals, soil, water, food, or indoor surfaces. Some fungi can cause infections or allergies in humans, especially in people with weakened immune systems or underlying diseases.

  • One of the most underdiagnosed and undertreated phenotypes of Severe Asthma: Fungal Asthma. 
  • Fungal Asthma is a type of allergic asthma that is triggered by exposure to certain fungi or molds in the environment. 
  • Fungal Asthma can cause persistent inflammation, mucus production, airway obstruction, and bronchial hyperresponsiveness. 
  • Fungi can Initiate Severe Autoimmune Diseases
  • Fungal Asthma can be hard to diagnose because it can mimic other types of asthma or respiratory infections. However, it requires specific tests and treatments to improve your symptoms and prevent lung damage.

Fungi can affect the lungs and airways of asthmatics in different ways. They can cause fungal sensitization, which means that the immune system reacts to fungal proteins or components as if they were harmful invaders. This can lead to inflammation, mucus production, bronchoconstriction, and remodeling of the airways. Fungal sensitization can also make the lungs more susceptible to other triggers or infections.

Fungi can also cause fungal infection, which means that they invade and multiply in the lungs or airways. This can cause tissue damage, inflammation, and immune activation. Fungal infection can also complicate or mimic other lung diseases, such as tuberculosis or pneumonia.

Fungal sensitization or infection can occur with different types of fungi, such as Alternaria, Aspergillus, Cladosporium, or Penicillium. However, one of the most common and serious forms of fungal involvement in severe asthma is allergic bronchopulmonary aspergillosis (ABPA). ABPA is a condition where the immune system overreacts to Aspergillus species, which are ubiquitous molds that can grow on decaying organic matter or in moist environments. ABPA can cause severe asthma symptoms, lung damage, bronchiectasis (widening and scarring of the airways), and pulmonary fibrosis (hardening and scarring of the lung tissue).

How do you know if you have fungal sensitization or infection in your lungs or airways? Unfortunately, there is no simple or definitive test for this. The diagnosis of fungal sensitization or infection depends on a combination of clinical and immunological criteria, such as:

•  History of exposure to fungi or symptoms suggestive of fungal involvement

•  Skin testing with antigens derived from fungi or measurement of specific IgE levels in the blood

•  Chest imaging (such as X-ray or CT scan) showing signs of lung damage or infection

•  Sputum culture or analysis showing the presence of fungi or fungal components

•  Bronchoscopy (a procedure where a thin tube with a camera is inserted into the airways) showing signs of inflammation or infection

•  Biopsy (a procedure where a small sample of tissue is taken from the lungs) showing signs of inflammation or infection

The treatment of fungal sensitization or infection in severe asthma depends on the type and severity of the condition. The general goals of treatment are to:

•  Reduce the exposure to fungi or eliminate them from the environment

•  Control the asthma symptoms and prevent exacerbations

•  Reduce the inflammation and damage in the lungs and airways

•  Eradicate the fungal infection or reduce its load

The treatment options may include:

•  Asthma medications (such as bronchodilators, corticosteroids, leukotriene modifiers, biologics, etc.) to relieve the symptoms and prevent exacerbations

•  Antifungal medications (such as itraconazole, voriconazole, posaconazole, etc.) to kill or inhibit the growth of fungi

•  Immunotherapy (such as allergen-specific immunotherapy or omalizumab) to reduce the immune response to fungi

•  Surgery (such as lobectomy or pneumonectomy) to remove severely damaged parts of the lungs

The effectiveness and safety of these treatments may vary depending on the individual case and response. Therefore, it is important to consult with your doctor before starting any treatment and follow their instructions carefully.

How can you prevent fungal sensitization or infection in your lungs or airways? There are some measures that you can take to reduce your exposure to fungi or their effects on your health, such as:

•  Avoid or minimize contact with sources of fungi, such as compost, hay, soil, plants, animals, moldy food, or damp places

•  Use a mask, gloves, and protective clothing when handling or working with materials that may contain fungi

•  Clean and dry your home regularly and remove any visible mold or mildew

•  Use a dehumidifier or air conditioner to reduce the humidity and temperature in your home

•  Use a high-efficiency particulate air (HEPA) filter or vacuum cleaner to remove airborne fungi or dust from your home

•  Avoid smoking or exposure to secondhand smoke, as it can damage your lungs and increase your risk of infection

•  Take your asthma medications as prescribed and monitor your symptoms and lung function regularly

•  Seek medical attention promptly if you have any signs or symptoms of fungal sensitization or infection, such as worsening asthma, fever, cough, chest pain, weight loss, or blood in the sputum

Fungi can be a hidden but serious threat for people with severe asthma. However, with proper diagnosis, treatment, and prevention, you can manage your condition and improve your quality of life. If you have any questions or concerns about fungi and severe asthma, talk to your doctor or healthcare provider.

We hope you found this blog post informative and helpful. We would like to thank the author of the paper “A mammalian lung’s immune system minimizes tissue damage by initiating five major sequential phases of defense” for their contribution to the scientific knowledge on this topic. You can read the full paper here: <a href=”https://link.springer.com/article/10.1007/s10238-023-01083-4″>https://link.springer.com/article/10.1007/s10238-023-01083-4</a>

If you want to learn more about the World Asthma Foundation and our efforts to improve the lives of people with asthma, please visit our website: <a href=”https://worldasthmafoundation.org/”>https://worldasthmafoundation.org/</a>

Thank you for reading and stay tuned for more updates from us!

Sources:

How Major Fungal Infections Can Initiate Severe Autoimmune Diseases

https://www.sciencedirect.com/science/article/abs/pii/S0882401021004745#:~:text=However%2C%20major%20fungal%20infections%20can,fungal%20infections%2C%20including%20antibiotic%20usage.

Unraveling the Role of Candidalysins in Severe Asthma

Candida Albicans

Welcome Message from the World Asthma Foundation

Hello to our dedicated community and newcomers alike.

The World Asthma Foundation (WAF) continues its mission to Defeat Asthma by fostering awareness, enhancing education, and promoting research to unravel the complexities of Asthma. We appreciate your interest and partnership as we work towards a world where Asthma is no longer a limiting factor in anyone’s life.

Building on our recent blog post discussing Candida’s role in inflammation and autoimmune response and its implications for severe Asthma, we’re excited to delve deeper into one of Candida’s potent weapons, Candidalysins. This topic is the focus of intensive research globally, including groundbreaking work from the Mayo Clinic, and shows promising potential in understanding the pathogenesis and exacerbation of severe asthma.

Thank you for being part of our mission. We encourage you to share this information with your healthcare provider and engage in open, productive conversations about your health.

Introduction

Last week, we explored the intricate interplay between Candida colonization, dysbiosis, inflammation, autoimmune responses, TNF-alpha dysregulation, and comorbidities in the pathogenesis and exacerbation of severe asthma. A critical piece of the puzzle involves a protein secreted by Candida, Candidalysins. These proteins play a significant role in Candida’s virulence and are instrumental in driving the inflammatory response, making them a critical research focus in the context of Asthma.

Candidalysins: A Closer Look

Candida albicans produces a group of cytolytic peptide toxins known as Candidalysins, which disrupt host epithelial barriers, leading to infection and promoting inflammation. Recent research indicates that Candidalysins also exacerbate the severity of asthma by enhancing airway inflammation, making the study of these proteins crucial in understanding and managing severe asthma.

The Inflammatory Role of Candidalysins

Candidalysins are known to damage epithelial cells, triggering an inflammatory response. In the context of asthma, this inflammation can intensify symptoms and exacerbate the severity of the condition. Understanding the specific role of Candidalysins in promoting this inflammation can provide insights into new therapeutic strategies for managing severe asthma.

Candidalysins and Immune Response

Research indicates that Candidalysins play a vital role in triggering a strong immune response, affecting immune cell recruitment and activation. This response is critical in the progression of asthma and can provide potential targets for therapeutic intervention.

Implications for Severe Asthma

The role of Candidalysins in promoting inflammation and triggering immune responses has significant implications for severe asthma. Understanding these implications is crucial for developing more effective management strategies, diagnostic tools, and potential treatments.

Candida in Pulmonary Secretions: A New Study

In addition to the role of Candidalysins in severe asthma, we also want to highlight another recent study that may be relevant to our readers. This study, published in The Open Respiratory Medicine Journal, examined the presence and significance of Candida in pulmonary secretions of patients with bronchitis, mucus plugging, and atelectasis. These are conditions that can affect people with asthma and make breathing difficult. The study found that Candida was often associated with these conditions and may play a role in causing or worsening them. The study also found that patients with Candida in their lungs had a higher risk of respiratory failure and death. The study suggested that treating Candida with antifungal drugs may help some patients improve their lung function and outcomes. However, the study was not conclusive and more research is needed to confirm these findings. This study adds to the growing evidence that Candida may be more than just a harmless colonizer of the lungs and may have important implications for severe asthma. You can read more about this study here.

Conclusion

Research into Candidalysins and their role in severe asthma is ongoing and promising. These cytolytic toxins provide a unique perspective on how Candida can influence the severity and progression of asthma, offering potential new avenues for therapeutic intervention. Another recent study also suggests that Candida may affect lung function and outcomes by causing or worsening bronchitis, mucus plugging, and atelectasis in some patients. These findings indicate that Candida may be more than just a harmless colonizer of the lungs and may have important implications for severe asthma. We’re excited to bring you the latest research on this subject and appreciate your interest and involvement in the Defeat Asthma mission. As we continue to unravel the complexities of Asthma, we hope to empower our readers with knowledge and tools to manage this chronic condition.

The Future of Asthma Research

As we understand more about the interactions between the Candidalysins and our body’s immune response, we will continue to see developments in diagnostic tools and therapies. Unraveling this complex relationship is critical in determining the trajectory of severe asthma and holds the key to future breakthroughs in its management.

Your Role in Our Mission

Our readers are a crucial part of our mission to Defeat Asthma. As we continue to share insights from the latest research, we encourage you to keep informed and to share these findings with your network. Conversations about research like this can help increase public understanding of Asthma, combat stigma, and ultimately contribute to better outcomes for those living with Asthma.

What’s Coming Up Next

In our upcoming posts, we will continue to keep you updated on research into the role of Candidalysins and other pathogenic factors contributing to severe asthma. We will also be delving into lifestyle and environmental factors that affect asthma, and how we can manage these to better control this chronic condition.

Stay Tuned for More

Stay connected with us to get the latest information and insights in the world of Asthma research, management, and advocacy. Subscribe to our newsletter, follow us on social media, and share our resources with your community.

Thank You

Thank you for being a part of the World Asthma Foundation community. Your involvement, whether as a reader, donor, advocate, or patient, is critical in our fight to Defeat Asthma. We appreciate your commitment and look forward to a future where Asthma no longer limits anyone’s potential.

How Th17-high asthma is affected by IL-17 and what you can do about it

Hello and welcome to the World Asthma Foundation blog, where we share the latest news and insights on asthma research and treatment. We are a nonprofit organization dedicated to improving the lives of people with asthma and advancing the science of asthma prevention and cure. Our mission is to raise awareness, educate, and advocate for asthma patients and their families. Our vision is a world free of Asthma.

If you are a Severe Asthmatic, you may have a subtype of asthma called Th17-high asthma. This subtype is characterized by high levels of a molecule called IL-17 in your airways. IL-17 is produced by a type of immune cell called Th17 cell. Th17 cells are normally involved in protecting the body from certain bacteria and fungi. However, in some cases, they can become overactive and produce too much IL-17.

IL-17 is a powerful inflammatory molecule that can worsen your asthma symptoms by:

• Attracting other immune cells, such as neutrophils, to your airways

• Activating tissue cells to secrete mucus and contract airway smooth muscle

• Inducing the production of other inflammatory molecules that cause more damage

• Interfering with the action of steroids, which are the main drugs used to treat asthma

In this blog post, we will explain how IL-17 affects Th17-high asthma and what you can do about it.

How IL-17 affects Th17-high asthma
IL-17 plays a key role in driving neutrophilic inflammation in Th17-high asthma. Neutrophils are a type of white blood cell that fight infections and inflammation. However, in Th17-high asthma, they accumulate in the airways and cause damage to the lung tissue. This leads to more severe asthma symptoms and poor response to conventional treatments.

IL-17 can stimulate neutrophils to release harmful substances that can damage the airway lining and cause mucus production, airway narrowing, and airway remodeling.

IL-17 can also make asthma worse by interfering with the action of steroids. Steroids work by suppressing inflammation and reducing the activity of immune cells. However, IL-17 can make some immune cells resistant to steroids, which means that steroids may not work as well for some severe asthmatics.

What you can do about IL-17.

One possible strategy to treat Th17-high asthma is to block IL-17 or its receptor with drugs that can prevent IL-17 from binding to its targets and causing inflammation. Several such drugs have been developed and tested in clinical trials for various inflammatory diseases, such as psoriasis, rheumatoid arthritis, and Crohn’s disease. Some of these drugs have also been tested in Severe Asthmatics who have high levels of IL-17 or neutrophils in their airways.

The results of these trials have been mixed. Some studies have shown that blocking IL-17 can improve lung function, reduce exacerbations, and lower the need for oral steroids in severe asthmatics. Other studies have shown no benefit or even worse outcomes with IL-17 blockers. The reasons for these discrepancies are not clear yet, but may depend on factors such as the type of IL-17 blocker used, the dose and duration of treatment, the characteristics of the patients enrolled, and the endpoints measured.

Therefore, more research is needed to determine whether blocking IL-17 is a viable option for treating severe asthma. We also need to identify which patients are most likely to benefit from this approach and how to monitor their response and safety. We also need to explore other ways to modulate IL-17 production or function in severe asthmatics.

In addition to pharmacological interventions, there are also some lifestyle changes that may help reduce IL-17 levels and improve asthma control. These include:

• Avoiding or reducing exposure to triggers that may activate Th17 cells, such as allergens, infections and pollution

• Eating a balanced diet that contains anti-inflammatory foods, such as fruits, vegetables, nuts and fish

• Exercising regularly, but not too intensely, as moderate exercise can reduce inflammation and improve lung function

• Managing stress levels, as stress can increase inflammation and worsen asthma symptoms

If you have asthma, it is important to consult your doctor regularly and follow their advice on how to manage your condition. Your doctor may perform some tests to determine your asthma subtype and prescribe the best treatment for you.

By understanding how IL-17 affects your asthma and taking steps to reduce its impact, you may be able to breathe easier and enjoy a better quality of life.

We hope that this blog post has given you some insight into the role of IL-17 in severe asthma and the potential challenges and opportunities for targeting it. We will continue to update you on this topic as new findings emerge. In the meantime, if you have any questions or comments, please feel free to contact us or leave a comment below.

Thank you for reading and stay tuned for more blog posts from the World Asthma Foundation. Together we can defeat asthma.

How a Common Bacterium Can Trigger and Worsen Your Asthma

Introduction

Hello and welcome to the World Asthma Foundation blog, where we share the latest news and information on asthma and related topics. We are a non-profit organization that pursues our mission and vision with a strategy to support the asthma community with educational resources. Our goal is to foster improved outcomes, better doctor-patient relationships, and support joint decision-making. In this way, asthmatics can take charge of their own health.

One of our main areas of focus is Infectious Asthma, which is a term that describes asthma that is triggered or worsened by infections, such as bacteria, viruses, fungi or parasites. Infectious Asthma can affect anyone, but it is more common and severe in children, elderly, immunocompromised or low-income populations. Infectious Asthma can cause more frequent and severe asthma attacks, lung damage, chronic sinusitis, nasal polyps and other complications.

In this article, we will review the current knowledge on one of the most common and potentially harmful triggers of Infectious Asthma: Staphylococcus aureus (S. aureus), a bacterium that can colonize the skin and mucous membranes of humans. S. aureus can produce various toxins, such as staphylococcal enterotoxins (SE), that can act as superantigens and induce an intense immune response in the airways. This can result in increased production of immunoglobulin E (IgE), a type of antibody that mediates allergic reactions, and activation of eosinophils, a type of white blood cell that causes inflammation and tissue damage.

We will also discuss how measuring SE specific IgE (SE-IgE) may help to identify a subgroup of patients with severe asthma who may benefit from specific interventions. Finally, we will provide some key takeaways and recommendations for asthmatics and clinicians.

We hope that this article will be informative and helpful for you. If you have any questions or comments, please feel free to contact us. Thank you for reading.

Summary

In this article, we have reviewed the current knowledge on the role of S. aureus and its enterotoxins in asthma, especially severe asthma. We have summarized the main findings from five recent studies that have investigated the association between SE sensitization and asthma severity, phenotype and inflammation. We have also discussed how measuring SE-IgE may help to phenotype asthmatics and guide treatment decisions. We have provided some key takeaways and recommendations for asthmatics and clinicians. Here are the main points:

•  S. aureus and its enterotoxins are important factors in the pathogenesis of asthma, especially severe asthma.

•  SE can act as superantigens and induce an intense T cell activation causing local production of polyclonal IgE and resultant eosinophil activation.

•  SE can also manipulate the airway mucosal immunology at various levels via other proteins, such as serine-protease-like proteins (Spls) or protein A (SpA), and trigger the release of IL-33, type 2 cytokines, mast cell mediators and eosinophil extracellular traps.

•  SE sensitization is associated with increased risk of asthma, more asthma exacerbations, nasal polyps, chronic sinusitis, lower lung function and more intense type-2 inflammation.

•  SE sensitization is also linked to allergic poly-sensitization and allergic multimorbidity, such as rhinitis, eczema and food allergy, indicating a possible role of S. aureus in the development of allergic diseases.

•  Measuring SE-IgE may help to identify a subgroup of patients with severe asthma who may benefit from specific interventions, such as anti-IgE therapy or antibiotics.

Key Takeaways

•  Asthmatics should be aware of the potential role of S. aureus and its enterotoxins in triggering and worsening their asthma symptoms and seek medical advice if they suspect an infection or colonization.

•  Asthmatics should avoid contact with S. aureus carriers or sources of contamination, such as contaminated food or water, and practice good hygiene and wound care to prevent infection or colonization.

•  Asthmatics should ask their doctors about testing for SE-IgE as part of their asthma phenotyping and management, as it may help to identify a subgroup of patients with severe asthma who may benefit from specific interventions.

•  Clinicians should consider measuring SE-IgE in asthmatics, especially those with severe asthma, nasal polyps, chronic sinusitis or allergic multimorbidity, as it may provide valuable information on the underlying mechanisms and phenotypes of asthma and suggest novel therapeutic targets and strategies.

•  Clinicians should also monitor the SE-IgE levels and response to treatment in asthmatics who are receiving anti-IgE therapy or antibiotics, as it may help to evaluate the efficacy and safety of these interventions.

Conclusion

Asthma is a complex and heterogeneous disease that can be influenced by various factors, such as allergens, irritants, infections and stress. Among these factors, S. aureus and its enterotoxins have emerged as important triggers and modulators of asthma, especially severe asthma. SE can act as superantigens and induce an intense immune response in the airways, resulting in increased production of IgE and activation of eosinophils. SE can also manipulate the airway mucosal immunology at various levels via other proteins, such as Spls or SpA, and trigger the release of IL-33, type 2 cytokines, mast cell mediators and eosinophil extracellular traps. These mechanisms can lead to more severe asthma phenotype and type-2 inflammation.

SE sensitization is associated with increased risk of asthma, more asthma exacerbations, nasal polyps, chronic sinusitis, lower lung function and more intense type-2 inflammation. SE sensitization is also linked to allergic poly-sensitization and allergic multimorbidity, such as rhinitis, eczema and food allergy, indicating a possible role of S. aureus in the development of allergic diseases. Measuring SE-IgE may help to identify a subgroup of patients with severe asthma who may benefit from specific interventions, such as anti-IgE therapy or antibiotics.

In this article, we have reviewed the current knowledge on the role of S. aureus and its enterotoxins in asthma, especially severe asthma. We have summarized the main findings from five recent studies that have investigated the association between SE sensitization and asthma severity, phenotype and inflammation. We have also discussed how measuring SE-IgE may help to phenotype asthmatics and guide treatment decisions. We have provided some key takeaways and recommendations for asthmatics and clinicians.

We hope that this article has been informative and helpful for you. If you have any questions or comments, please feel free to contact us. Thank you for reading.

References

: Bachert C., Humbert M., Hanania N.A., Zhang N., Holgate S., Buhl R., Bröker B.M. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Eur Respir J. 2020;55(4):1901592. doi: 10.1183/13993003.01592-2019.

: Kanemitsu Y., Taniguchi M., Nagano H., Matsumoto T., Kobayashi Y., Itoh H. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol. 2012;130(2):376–382.e3. doi: 10.1016/j.jaci.2012.04.027.

: Soh J.Y., Lee B.W., Goh A. Staphylococcal enterotoxin specific IgE and asthma: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2013;24(3):270–279.e1-4. doi: 10.1111/pai.12056.

: Schleich F., Brusselle G.G., Louis R., Vandenplas O., Michils A., Van den Brande P., Lefebvre W.A., Pilette C., Gangl M., Cataldo D.D., et al. Asthmatics only sensitized to Staphylococcus aureus enterotoxins have more exacerbations, airflow limitation, and higher levels of sputum IL-5 and IgE. J Allergy Clin Immunol Pract. 2023;11(5):1658–1666.e4. doi: 10.1016/j.jaip.2023.01.021.

: James A., Gyllfors P., Henriksson E.L., Lundahl J., Nilsson G., Alving K., Nordvall L.S., van Hage M., Cardell L.O. Staphylococcus aureus enterotoxin sensitization is associated with allergic poly-sensitization and allergic multimorbidity in adolescents. Clin Exp Allergy. 2015;45(6):1099–1107. doi: 10.1111/cea.12519.

Sidebar: What is Staphylococcus aureus?

Staphylococcus aureus is a type of bacteria that can cause various infections in humans and animals. It is found in the environment and also in the normal flora of the skin and mucous membranes of most healthy individuals. It can colonize the anterior nares (the front part of the nose), the throat, the skin, and the gastrointestinal tract. It is estimated that up to half of all adults are colonized by S. aureus, and approximately 15% of them persistently carry it in their noses.

S. aureus can cause infections when it breaches the skin or mucosal barriers and enters the bloodstream or internal tissues. These infections can range from mild skin infections, such as boils or impetigo, to more serious infections, such as pneumonia, endocarditis, osteomyelitis, septic arthritis, or sepsis. S. aureus can also produce toxins that can cause food poisoning, toxic shock syndrome, or scalded skin syndrome.

S. aureus is a very adaptable and versatile bacterium that can acquire resistance to various antibiotics. The most notorious example is methicillin-resistant S. aureus (MRSA), which is resistant to most beta-lactam antibiotics, such as penicillins and cephalosporins. MRSA can cause infections both in community-acquired and hospital-acquired settings and poses a major public health challenge.

S. aureus is believed to have originated in Central Europe in the mid-19th century and has since evolved and diversified into many different strains or clones. Some of these strains are more virulent or resistant than others and have spread globally through human migration and travel. One of these strains is ST8, which includes the USA300 clone that is responsible for most community-acquired MRSA infections in the United States.

S. aureus is one of the most common and potentially harmful triggers of Infectious Asthma, especially severe asthma. It can produce various toxins, such as staphylococcal enterotoxins (SE), that can act as superantigens and induce an intense immune response in the airways. This can result in increased production of immunoglobulin E (IgE), a type of antibody that mediates allergic reactions, and activation of eosinophils, a type of white blood cell that causes inflammation and tissue damage.

References

: Staphylococcus aureus Infection – StatPearls – NCBI Bookshelf

: Global Epidemiology and Evolutionary History of Staphylococcus aureus ST45

: Origin, evolution, and global transmission of community-acquired … – PNAS

: Staphylococcus aureus Infections: Epidemiology, Pathophysiology 

How the microbiome affects asthma: new insights from a Spanish study

The World Asthma Foundation (WAF). WAF is a nonprofit organization dedicated to improving the lives of people with asthma through education, research, and advocacy. In this blog post, I want to share with you some exciting findings from a recent study on the microbiome and asthma, published by Spanish researchers in the journal Nutrients.

The microbiome is the collection of microorganisms that live in and on our bodies, such as bacteria, fungi, viruses, and parasites. The microbiome plays an important role in our health and immunity, and can also influence our susceptibility and response to various diseases, including asthma.

Asthma is a chronic inflammatory disease of the airways that affects millions of people worldwide. Asthma can be triggered by different factors, such as allergens, infections, pollution, stress, and diet. Asthma can also have different phenotypes (characteristics), such as allergic or non-allergic, eosinophilic or non-eosinophilic, mild or severe.

What is the microbiome and how does it affect asthma?

The study by Valverde-Molina and García-Marcos reviews the current evidence and challenges on the relationship between the microbiome and asthma, specifically how microbial dysbiosis (an imbalance of the microbial communities in the body) can influence the origins, phenotypes, persistence, and severity of asthma.

How different factors can influence the microbiome and asthma

The study explores how different factors, such as diet, environment, genetics, and infections, can affect the microbiome and asthma, and how modulating the microbiome could be a potential strategy for preventing or treating asthma. The study also reviews the different methods and techniques used to study the microbiome and its interactions with the immune system and the respiratory system.

The gut-lung axis: a key connection between the microbiome and asthma

One of the key points of the study is the importance of the gut-lung axis in the origin and persistence of asthma. The gut-lung axis is the concept that describes how the gut and lung microbiomes communicate with each other through various pathways, such as metabolites, cytokines, antibodies, and immune cells. The gut-lung axis can modulate inflammation and allergic responses in both organs.

The study shows that the process of microbial colonization in the first three years of life is fundamental for health, with the first hundred days of life being critical. Different factors are associated with early microbial dysbiosis, such as caesarean delivery, artificial lactation and antibiotic therapy, among others.

How microbial dysbiosis can lead to different asthma phenotypes and severity

Longitudinal cohort studies on gut and airway microbiome in children have found an association between microbial dysbiosis and asthma at later ages of life. A low ?-diversity (the number of different species) and relative abundance of certain commensal gut bacterial genera in the first year of life are associated with the development of asthma. Gut microbial dysbiosis, with a lower abundance of Phylum Firmicutes (a group of bacteria that includes lactobacilli), could be related with increased risk of asthma.

Upper airway microbial dysbiosis, especially early colonization by Moraxella spp. (a type of bacteria that can cause respiratory infections), is associated with recurrent viral infections and the development of asthma. Moreover, the bacteria in the respiratory system produce metabolites (substances produced by metabolism) that may modify the inception of asthma and its progression.

The role of the lung microbiome in asthma development has yet to be fully elucidated. Nevertheless, the most consistent finding in studies on lung microbiome is
the increased bacterial load (the number of bacteria) and the predominance of proteobacteria (a group of bacteria that includes Haemophilus spp. and Moraxella catarrhalis), especially in severe asthma.

Candida albicans: a fungal culprit in asthma development and exacerbation

The study also mentions Candida albicans (a type of fungus that can cause infections) as one of the fungal genera that can affect the gut and lung microbiome and asthma. Candida albicans can trigger inflammation and autoimmune responses in the body. Candida albicans can also induce a Th17 response (a type of immune response) in the gut and lungs. Candida albicans can also increase lung bacterial load and exacerbate airway inflammation.

This study is very relevant to our own research and findings on Candida’s role in inflammation and autoimmune response: implications for severe asthma. We published an article on this topic on our website on October 13th 2021 which features findings from Mayo Clinic researchers who examined how intestinal fungal microbiota affects lung resident memory CD4+ T cells (a type of immune cell) in patients with asthma.

You can find our article here: https://worldasthmafoundation.org/candidas-role-in-inflammation-and-autoimmune-response-implications-for-severe-asthma.htm

How modulating the microbiome could be a promising strategy for asthma prevention and treatment

We think that these studies complement each other well and provide valuable insights into this important and emerging topic. We believe that understanding the microbiome and its impact on asthma is crucial for developing new and effective strategies for prevention, diagnosis, and treatment of this chronic disease.

Candida’s Role in Inflammation and Autoimmune Response: Implications for Severe Asthma

Welcome Message from the World Asthma Foundation

Hello to our dedicated community and newcomers alike.

At the World Asthma Foundation (WAF), we’re united by a singular, important mission: to Defeat Asthma. Our approach is rooted in fostering awareness, enhancing education, and promoting research that seeks to unravel the complexities of Asthma. As we strive towards a world where Asthma is no longer a limiting factor in anyone’s life, we remain steadfast in bringing you timely, comprehensive, and relevant information.

We’re excited to share our latest blog post with you. This post encapsulates the culmination of the efforts of a variety researchers, clinicians, and organizations worldwide working independently including pioneering work from the Mayo Clinic, to shed light on the pathogenesis and exacerbation of severe asthma.

Mayo Clinic Candida Study

We delve into the compelling evidence pointing towards the intricate interplay between Candida colonization, dysbiosis, inflammation, autoimmune responses, TNF-alpha dysregulation, and comorbidities.

As we unravel these complex relationships, our hope is to equip you, our readers, with knowledge that can empower you in your journey with asthma or help you support someone who is affected.

Let’s continue to learn, share, and work together in our collective fight against Asthma.

Thank you for being a part of our mission. We encourage you to share this information with your healthcare provider.

Establishing a trustworthy and effective relationship with a healthcare provider is crucial to managing your health. It not only ensures that you get the best care but also allows for open and productive conversations about your health.

Introduction

Managing Severe Asthma remains a complex task for many pulmonary practitioners, despite available medication and trigger avoidance strategies. Frequent attacks and poor symptom control often plague patients. Recent investigations, pieced together by the World Asthma Foundation over time have uncovered dozens of notable research groups that have illuminated the complex relationship between Candida colonization, dysbiosis, inflammation, autoimmune response, TNF-alpha dysregulation, and comorbidities in the pathogenesis and exacerbation of Severe Asthma. This amassed knowledge underscores the multifaceted nature of Severe Asthma, bringing to light the critical role of Candida in the disease process.

Recent studies reveal a potential link between Candida colonization, dysbiosis, inflammation, autoimmune response, TNF-alpha dysregulation, and comorbidities in the pathogenesis and exacerbation of Severe Asthma. This article will provide an overview of these linkages, the financial impact on individuals and society, the necessity for improved diagnostic tools and processes, and source the scientific studies supporting these conclusions.

Candida Colonization, Dysbiosis, and Fungal Sensitization

Candida albicans, a common fungal inhabitant of the mouth, gut, and genital tract, can also colonize the respiratory tract. This colonization is often facilitated by dysbiosis, an imbalance in the normal microbial flora, which can be induced by various factors, including the use of antibiotics and changes in the host immune response. Further, fungal sensitization, a process where the immune system produces antibodies (IgE) against fungal allergens, plays a crucial role in the onset and severity of asthma symptoms. Studies from the Mayo Clinic underline the lower alpha-diversity of lung microbiota and higher fungal burdens in Asthma patients, showing a correlation with severity and poor control of Asthma.

Case in Point

A recent study presented at the CHEST Annual Meeting 2021 by researchers from Mayo Clinic and University of California Davis confirmed the association between intestinal fungal dysbiosis and asthma severity in humans, particularly hospital use in the past year. The study found that patients with asthma who had higher intestinal Candida burden were more likely to have severe asthma exacerbations in the previous year, independent of systemic antibiotic and glucocorticoid use. This suggests that intestinal fungal dysbiosis may worsen asthma control and outcomes in humans. The study also showed that intestinal fungal dysbiosis can enhance the severity of allergic asthma in mice by increasing lung resident group 2 innate lymphoid cells (ILC2) populations, which are important mediators of the gut-lung axis effect. The study used a novel technique of flow cytometry to identify and quantify ILC2 in the lungs of mice. These findings highlight the potential role of intestinal fungal dysbiosis and ILC2 in asthma pathogenesis and management.

Role of Antibiotics and Gut-Lung Axis

Studies show that certain antibiotics prescribed for infections, such as Helicobacter pylori, can lead to gut microbiota dysbiosis, promoting Candida colonization. This gut-lung axis, the communication between gut microbiota and lung health, can create an environment conducive to fungal overgrowth and subsequent infection. As such, understanding this interaction can offer valuable insights into asthma management. Research from the Mayo Clinic suggests that antibiotic usage can significantly contribute to these interactions and, consequently, the pathogenesis of Severe Asthma.

Mechanisms of Candida Colonization

Candida albicans utilizes several mechanisms to cross the intestinal epithelial barrier, including adherence to epithelial cells, invasion, and translocation. Each of these steps facilitates Candida’s ability to invade the host’s system and trigger an immune response. Insights from the Mayo Clinic suggest that bacterial-fungal interactions play a key role in these mechanisms and have implications for Candida colonization.

Candida-Induced Inflammation, Autoimmune Response, and TNF-alpha Dysregulation

Once established, Candida colonization can incite inflammation by provoking the immune system to produce pro-inflammatory cytokines, such as TNF-alpha. While TNF-alpha aids in fighting off infections by initiating inflammation, its dysregulation can lead to chronic inflammation and autoimmune diseases, enhancing the severity of asthma. Research from the Mayo Clinic has shown that Candida colonization in the lung induces an immunologic response, leading to more Severe Asthma.

Autoimmune Response, Comorbidities, and Severe Asthma

Recent studies propose that an autoimmune response could be involved in the onset and exacerbation of Severe Asthma, with TNF-alpha dysregulation playing a pivotal role. Comorbidities like rheumatoid arthritis, often seen in conjunction with Severe Asthma, can further complicate disease management and progression.

Burden, Financial Impact, and Comorbidities

Severe Asthma imposes a substantial burden on individuals and society, financially and otherwise. Healthcare costs, productivity loss, and reduced quality of life contribute to this impact. Asthma comorbidities such as autoimmune diseases can affect disease progression and outcomes, underscoring the need for a comprehensive management approach.

The Necessity for Improved Diagnostic Tools

An accurate diagnosis of Candida colonization, inflammation, and autoimmune response in severe asthma is crucial for optimal patient management. There’s a growing need for improved diagnostic methodologies, tools, and processes. Advances in diagnostic techniques, such as bronchoscopy and bronchoalveolar lavage (BAL), can offer valuable insights into Candida colonization and the associated inflammatory and autoimmune processes. The Mayo Clinic’s recent findings, which identify a unique pattern of lower alpha-diversity and higher fungal burden in the lung microbiota of severe asthma patients, further emphasize the need for enhanced diagnostic methods.

Conclusion

Understanding the link between Candida colonization, dysbiosis, inflammation, autoimmune response, TNF-alpha dysregulation, comorbidities, and severe asthma is crucial for medical practitioners dealing with this chronic disease. The significant burden and financial impacts of Severe Asthma on individuals and society underline the urgency for effective management strategies.

Recognizing the influence of comorbidities, such as autoimmune diseases, can guide comprehensive care plans for patients with Severe Asthma. Moreover, enhanced diagnostic tools and processes will aid in early identification and more personalized treatment approaches, ultimately improving patient outcomes.

By integrating this knowledge, medical practitioners can not only better understand the multifaceted nature of Severe Asthma but also enhance its overall management, leading to improved patient care. With ongoing research, we can continue to unravel the complex relationships and mechanisms in asthma pathogenesis, providing new avenues for therapeutic interventions and improved patient outcomes.

Research on the relationship between Candida albicans and Asthma is an important area of study that could lead to better understanding and management of Asthma. In the following sections, we will present a summary of various significant studies on the relationship between Candida Albicans colonization and asthma. We will also cover information on the microbiome of the gut and lungs, wherever applicable.

Additionally, we will provide key takeaways from each study, including relevant details such as the study’s title, authors, and organization affiliation. Finally, we will summarize the collective findings and scientific conclusions related to Candida Albicans colonization, sensitization, and infection in Asthma, and offer resources for you to share with your healthcare provider.

A comprehensive understanding of these aspects promises to shed light on the intricate mechanisms underlying severe asthma, offering new perspectives in our fight against this chronic condition.

Further Study

Name of study: Fungal Dysbiosis and Its Clinical Implications in Severe Asthma Patients
Date: 2023
Authors: Allison N. Imamura, Hannah K. Drescher, Mai Sasaki, Daniel J. Peaslee, David S. Crockett, Alexander S. Adams, Marcia L. Wills, Stephen C. Meredith, and Andrew H. Limper
Organization: Mayo Clinic, Rochester, MN
Summary: This study discusses the fungal dysbiosis in severe asthma patients. It finds that the lower alpha-diversity of lung microbiota and higher fungal burdens correlate with severity and poor control of asthma. The study also discusses the possible role of antibiotic usage and bacterial-fungal interactions in this process. The study concludes that understanding the link between Candida colonization, inflammation, autoimmune response, and Severe Asthma is crucial for better management of this chronic disease.

Study Title: CANDIDA ALBICANS INTESTINAL DYSBIOSIS INCREASES LUNG RESIDENT ILC2 POPULATIONS AND ENHANCES THE SEVERITY OF HDM-INDUCED ALLERGIC ASTHMA IN MICE

•  Date: October 17-20, 202

Authors: Amjad Kanj, Theodore Kottom, Kyle Schaefbauer, Andrew Limper, Joseph Skalski

•  Organization Affiliation: Mayo Clinic and University of California Davis

Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell 2019. The authors are Petra Bacher, Thordis Hohnstein, Eva Beerbaum, Marie Röcker, Matthew G. Blango, Svenja Kaufmann, Jobst Röhmel, Patience Eschenhagen, Claudia Grehn, Kathrin Seidel, Volker Rickerts, Laura Lozza, Ulrik Stervbo, Mikalai Nienen, Nina Babel, Julia Milleck, Mario Assenmacher, Oliver A. Cornely, Maren Ziegler, Hilmar Wisplinghoff, Guido Heine, Margitta Worm, Britta Siegmund, Jochen Maul, Petra Creutz, Christoph Tabeling, Christoph Ruwwe-Glösenkamp, Leif E. Sander, Christoph Knosalla, Sascha Brunke, Bernhard Hube, Olaf Kniemeyer, Axel A. Brakhage and Carsten Schwarz.
The main objective of the article is to investigate how cross-reactivity against Candida albicans influences human anti-fungal Th17 immunity and pathology.
• C. albicans-specific Th17 cells can cross-react with other fungal antigens and gluten peptides in patients with CeD or asthma.
• Cross-reactive Th17 cells can cause immune pathology in the gut and lung by producing IL-17A and IL-22 cytokines.
Candida and asthma better by showing that Candida can induce a specific type of immune response that can also react to other fungi and allergens that are associated with asthma. The article also suggests that Candida may contribute to the severity and chronicity of asthma by causing inflammation and tissue damage in the lung. mechanisms and consequences of cross-reactivity are complex and need further investigation.

Name of study: Candida auris: Epidemiology, biology, a:Authors:ntifungal resistance, and virulence
Date: 2020
Authors: Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G.
M

Name of study: Candida albicans pathogenicity and epithelial immunity
Date: 2014

Abstract Naglik, J. R., Richardson, J. P., & Moyes, D. L.
URL:

Name of study: Candida albicans interactions with the host: crossing the intestinal epithelial barrier
Date: 2019

Abstract: [Unavailable in given data]
Authors: Basmaciyan, L., Bon, F., Paradis, T., Lapaquette, P., & Dalle, F.
URL: https://doi.org/10.1080/21688370.2019.1612661

Name of study: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
Date: 2017
Abstract: Authors: Chey WD, Leontiadis GI, Howden CW, Moss SF.
URL: https://doi.org/10.1038/ajg.2016.563

Name of study: Asthma is inversely associated with Helicobacter pylori status in an urban population
Date: 2008

Abstract: [Unavailable in given data]
Authors: Reibman J, Marmor M, Filner J, et al.
URL: https://doi.org/10.1371/journal.pone.0004060

Name of resource: H pylori Probiotics: A Comprehensive Overview for Health Practitioners
Date: 2020
Abstract: Authors: Ruscio M.
URL: https://drruscio.com/h-pylori-probiotics/

Name of resource: Treatment regimens for Helicobacter pylori in adults
Date: 2022

Abstract:
Authors: Lamont JT.

Name of study: Effects of probiotics on the recurrence of bacterial vaginosis: a review
Date: 2014
Abstract:
Authors: Homayouni A, Bastani P, Ziyadi S, et al.

How to Live Well with Asthma in the Post-COVID Era

The COVID-19 pandemic has been a tough time for everyone, especially for people with asthma. Asthma is a chronic condition that affects the airways and makes it hard to breathe. People with asthma may have more severe symptoms or complications if they get infected with COVID-19. That’s why it’s important to know how to manage your asthma and protect yourself from the virus.

But even as the pandemic seems to be winding down, the challenges are not over for people with asthma. Many people still live in fear of getting sick or infecting others. Many people still face stress, anxiety, depression, or isolation due to the pandemic. Many people still struggle with access to health care or vaccines.

That’s why we need to learn how to live well with asthma in the post-COVID era. In this blog post, we will share some insights from recent studies and some tips on how to cope with the physical and mental health challenges of asthma and COVID-19.

Summary

The COVID-19 pandemic has had a significant impact on the quality of life and treatment of asthma patients around the world. A recent study by Naglaa Youssef and colleagues surveyed 200 asthma patients in Egypt and found that 80% of them had uncontrolled asthma, meaning that their symptoms were frequent or severe and interfered with their daily activities. The most common factor that affected their quality of life was the limitation of activity, such as exercise, work, or socializing. Women reported a higher level of perceived threat from COVID-19 than men.

The study also found some positive changes in the patients’ health behaviors during the pandemic. More patients visited their clinician regularly and followed their treatment plan than before the pandemic. However, over 75% of the patients could not tell the difference between asthma and COVID-19 symptoms, which could lead to confusion or delay in seeking medical help.

The study concluded that the COVID-19 pandemic improved some aspects of asthma care, but also highlighted the need for better asthma control and education. Uncontrolled asthma is a major risk factor for poor quality of life and should be addressed by both patients and clinicians.

Another study by Valeria Saladino and colleagues explored the psychological and social effects of the pandemic on the population, mostly children, college students, and health professionals. They found that these groups were more likely to develop post-traumatic stress disorder, anxiety, depression, and other symptoms of distress due to the pandemic. They also found that social distancing and security measures affected the relationship among people and their perception of empathy toward others.

The study suggested that telepsychology and technological devices could be useful tools to decrease the negative effects of the pandemic and improve psychological treatment of patients online. Telepsychology is the delivery of psychological services using telecommunication technologies, such as phone calls, video calls, or online platforms. Telepsychology can offer benefits such as convenience, accessibility, affordability, and continuity of care.

Key takeaways

Here are some key takeaways on how to live well with asthma in the post-COVID era:

• Keep your asthma under control. Follow your asthma action plan, take your medications as prescribed, monitor your symptoms and peak flow, and avoid triggers that can worsen your asthma.

• Protect yourself from COVID-19. Follow the public health guidelines to prevent the spread of the virus. Wear a mask when you are in public places, wash your hands frequently, practice social distancing, and get vaccinated when it’s available for you.

• Seek medical help when needed. Don’t hesitate to contact your clinician if you have any questions or concerns about your asthma or COVID-19. If you have symptoms of COVID-19, such as fever, cough, shortness of breath, or loss of taste or smell, get tested and isolate yourself until you get the results.

• Stay active and healthy. Physical activity can improve your lung function and overall health. Choose activities that are suitable for your fitness level and don’t trigger your asthma. Eat a balanced diet, drink plenty of water, and get enough sleep.

• Seek support and information. Living with asthma can be stressful and isolating, especially during a pandemic. Reach out to your family, friends, or support groups for emotional support. You can also visit the World Asthma Foundation website to learn more about asthma and how to manage it during the pandemic.

• Practice empathy. Empathy is the ability to understand and share the feelings of another person. It can help you to care for others, cooperate with them, and support them in times of need. Empathy can also motivate you to follow public health guidelines and get vaccinated to prevent the spread of the virus.

• Use telepsychology. Telepsychology is a convenient and effective way to access psychological services online. It can help you cope with stress, anxiety, depression, or other mental health problems caused by the pandemic. It can also help you improve your relationship with yourself and others.

Conclusion

Asthma is a common chronic condition that can impair your quality of life if it’s not well controlled. The COVID-19 pandemic has added more challenges and risks for people with asthma. However, by following some simple steps, you can live well with asthma in the post-COVID era.

The World Asthma Foundation is a non-profit organization that aims to empower the world asthma community through education, collaboration, and advocacy. Our vision is to see a day where they can improve the quality of lifem for all asthmatics.
We do this by advocating for an improved understanding
of the causes, diagnostic tools, methodologies, precision therapies, prevention, sustainability in healthcare, and one day
a cure.

Together, we can makea difference for people living with asthma.

Shedding Light on T2-Low Asthma: A Forgotten Frontier in Asthma Research

Introduction:

Welcome to the World Asthma Foundation blog, where we strive to inform and inspire our readers in support of our mission. Today, we turn our attention to a lesser-known aspect of asthma called T2-Low asthma. While much focus has been placed on T2-High asthma, which includes allergic and non-allergic inflammation, T2-Low asthma has remained in the shadows. This subtype encompasses various forms, such as paucigranulocytic asthma, Type 1 and Type-17 inflammation, and the neutrophilic form, which is particularly common in severe or refractory cases. By exploring the realm of T2-Low asthma, we hope to raise awareness, ignite discussion, and rally the asthma community towards much-needed research and innovation.

Subheading: Unraveling the Complexity of T2-Low Asthma

Understanding T2-Low Asthma:

T2-Low asthma comprises different subtypes, including paucigranulocytic asthma, Type 1 and Type-17 inflammation, and the prevalent neutrophilic form. While T2-Low asthma is generally associated with milder symptoms, it’s important to note that the neutrophilic form can result in severe or refractory cases. By recognizing the complexities of T2-Low asthma, we can gain a deeper understanding of the challenges it poses to patients and researchers alike.

The Need for Research:

Despite its impact on patients, T2-Low asthma has received limited attention in terms of biomarkers and effective treatments. The scarcity of research on T2-Low asthma hinders progress in developing targeted therapies and diagnostic tools. By emphasizing the need for increased research efforts, we can work towards improving the lives of individuals living with T2-Low asthma.

Subheading: Key Takeaways

Key Takeaways:

T2-Low asthma encompasses various subtypes, including paucigranulocytic asthma, Type 1 and Type-17 inflammation, and the neutrophilic form.
While T2-Low asthma is generally associated with milder symptoms, the neutrophilic form can result in severe or refractory cases.
Limited research has been conducted on T2-Low asthma, leading to a lack of biomarkers and effective treatments.
Raising awareness and supporting research on T2-Low asthma is crucial to unlocking innovative solutions and improving outcomes for patients.
The World Asthma Foundation is dedicated to addressing the gaps in T2-Low asthma research and advocating for the needs of affected individuals.
Conclusion:

As we conclude our exploration of T2-Low asthma, we invite you to take action and support the cause. T2-Low asthma remains an understudied and overlooked frontier in asthma research, leaving many patients without effective treatments or biomarkers. It is our collective responsibility to raise awareness, push for solutions, improve diagnostics, and ultimately strive for a cure. By joining hands with the World Asthma Foundation, we can make a significant impact on the lives of those affected by T2-Low asthma. Together, we can transform the future of asthma care and provide hope for a brighter tomorrow.

Transforming Asthma Research: Unveiling the Link Between Laundry Detergents and Eosinophilic Airway Inflammation

Introduction:

Welcome to the World Asthma Foundation’s latest blog post, where we delve into groundbreaking research that sheds light on a previously unknown connection between laundry detergents and eosinophilic airway inflammation. Asthma affects millions worldwide, and our mission at the World Asthma Foundation is to inform and inspire, driving progress in the understanding and management of this condition. In this article, we explore a recent study by Kyoko Saito et al., which uncovers the mechanisms behind laundry detergents’ impact on airway health, aligning with our commitment to improving the lives of severe asthmatics.

Investigating the Impact of Laundry Detergents on Airway Inflammation

Summary:

In this groundbreaking study, researchers investigated the direct effects of laundry detergents and surfactants on airway inflammation. The findings demonstrated a significant correlation between the use of certain detergents and the development of eosinophilic airway inflammation, along with the activation of group 2 innate lymphoid cells (ILC2s). Moreover, the study identified the involvement of IL-33 expression and oxidative stress in this process. These discoveries hold immense potential for advancing our understanding of asthma triggers and guiding the development of targeted interventions.

Key Takeaways:

Laundry detergents and surfactants have been found to directly induce eosinophilic airway inflammation in vivo, shedding light on a previously unknown asthma risk factor.
Activation of group 2 innate lymphoid cells (ILC2s) plays a pivotal role in the development of detergent-induced airway inflammation.
Increased IL-33 expression in airway epithelial cells, triggered by laundry detergents, is a key contributor to the inflammatory response.
Oxidative stress has been identified as a mediator in the detergent-induced airway inflammation, offering potential targets for future therapeutic interventions.
The presence of detergent residues in house dust further emphasizes the relevance of this study, highlighting the daily exposure of individuals to these triggers.Conclusion:

The World Asthma Foundation is proud to share this groundbreaking research, which uncovers a new understanding of the impact of laundry detergents on airway inflammation. By illuminating the mechanisms behind this phenomenon, we take a significant step forward in the fight against asthma. This study reinforces the importance of our mission to inform, inspire, and engage severe asthmatics, rallying them to join our cause. Together, we can drive further research, advocate for improved asthma management strategies, and make a tangible difference in the lives of millions.